These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15641472)

  • 1. [Obesity and dyslipidemias].
    Troyo-Barriga P
    Gac Med Mex; 2004; 140 Suppl 2():S49-58. PubMed ID: 15641472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and dyslipidemia.
    Repas T
    S D Med; 2011 Jul; 64(7):241-3, 245, 247 passim. PubMed ID: 21848021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemia in the metabolic syndrome: clinical implications and management.
    Hafidh SA; Lavie CJ; Burns BP; Khan SS; Alpert MA
    Minerva Cardioangiol; 2006 Apr; 54(2):215-27. PubMed ID: 16778753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDL particle size, fat distribution and insulin resistance in obese children.
    Miyashita M; Okada T; Kuromori Y; Harada K
    Eur J Clin Nutr; 2006 Mar; 60(3):416-20. PubMed ID: 16278685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Search for an optimal atherogenic lipid risk profile: from the Framingham Study.
    Nam BH; Kannel WB; D'Agostino RB
    Am J Cardiol; 2006 Feb; 97(3):372-5. PubMed ID: 16442398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ
    Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
    Kontush A; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors.
    Quijada Z; Paoli M; Zerpa Y; Camacho N; Cichetti R; Villarroel V; Arata-Bellabarba G; Lanes R
    Pediatr Diabetes; 2008 Oct; 9(5):464-71. PubMed ID: 18507788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between educational status and cardiovascular risk factors in an overweight and obese Turkish female population.
    Tanyolaç S; Sertkaya Cikim A; Doğan Azezli A; Orhan Y
    Anadolu Kardiyol Derg; 2008 Oct; 8(5):336-41. PubMed ID: 18849223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population.
    Whayne TF
    Indian Heart J; 2007; 59(3):218-25. PubMed ID: 19124929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vascular inflammation: effect of proatherogenic dyslipidemic trio or quartet].
    Zamaklar M; Lalić K; Lalić N
    Med Pregl; 2009; 62 Suppl 3():37-42. PubMed ID: 19702114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.
    Maki KC; Galant R; Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):59K-64K; discussion 34K-35K. PubMed ID: 16291016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic management of isolated low high-density lipoprotein syndrome.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China].
    Zhao WH; Zhang J; You Y; Man QQ; Li H; Wang CR; Zhai Y; Li Y; Jin SG; Yang XG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2005 Sep; 39(5):306-10. PubMed ID: 16266538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifetime risk for developing dyslipidemia: the Framingham Offspring Study.
    Cobain MR; Pencina MJ; D'Agostino RB; Vasan RS
    Am J Med; 2007 Jul; 120(7):623-30. PubMed ID: 17602937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
    Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
    Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.